The novel selective antibody sibeprenlimab reduced proteinuria more than any prior drug for IgA nephropathy, with excellent ...

Vera Therapeutics (NASDAQ:VERA) fell ~32% in the premarket on Friday after late-stage trial data indicated that the company’s ...

New 100-week data from the ongoing Phase I/II study of zigakibart, an investigational anti-APRIL monoclonal antibody, ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

Overall, administration of felzartamab was generally well tolerated ... need for additional treatments to address high-risk IgA nephropathy,” said Uptal Patel, M.D., Head of Development, HI ...

IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface. A recent Phase 2 trial revealed that felzartamab, an ...

A top ERA abstract presents a biomarker-based model that non-invasively estimates kidney fibrosis in patients with IgA ...

New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal antibody, ...

Panelists discuss how step-therapy for immunoglobulin A (IgA) nephropathy is evolving toward a more personalized approach, ...

“This is promising news for patients and supports the potential of felzartamab to be a meaningful treatment option for people living with IgA nephropathy, a leading cause of chronic kidney disease.